

Establishing reference intervals for serum glutathione reductase in healthy adults

Qian Liu^{1,2,3,4}, Hongxia Wang⁵, Shanshan Shen^{1,2,3,4}, Fang Yang^{1,2,3,4}, Zongze Han^{1,2,3,4}, Enyue Liu⁵, Fumeng Yang^{1,2,3,4*}

¹Department of Laboratory Medicine, Lianyungang Clinical College, Jiangsu University & The Second People's Hospital of Lianyungang, Lianyungang, China

²Department of Laboratory Medicine, Lianyungang Clinical College, Xuzhou Medical University & The Second People's Hospital of Lianyungang, Lianyungang, China

³Department of Laboratory Medicine, The Second People's Hospital of Lianyungang Affiliated with Kangda College of Nanjing Medical University, Lianyungang, China

⁴Department of Laboratory Medicine, Lianyungang Clinical College, Bengbu Medical University & The Second People's Hospital of Lianyungang, Lianyungang, China

⁵Department of Laboratory Medicine, Chengcheng County Hospital, Weinan, China

***Corresponding author:**

Fumeng Yang
The Second People's
Hospital of Lianyungang
China
E-mail: yfm31095018@163.
com

Submitted: 22 September 2024; **Accepted:** 26 December 2024

Online publication: 28 February 2025

Arch Med Sci 2025; 21 (4): 1397–1404

DOI: <https://doi.org/10.5114/aoms/199536>

Copyright © 2025 Termedia & Banach

Abstract

Introduction: Glutathione reductase (GR) is a key enzyme that catalyzes the reduction of oxidized glutathione to its reduced form, playing a vital role in protecting cells from oxidative damage caused by the accumulation of reactive oxygen species. This study employed the ultraviolet enzymatic method to measure serum GR activity, aiming to investigate its distribution among apparently healthy adults and preliminarily establish reference intervals for serum GR.

Material and methods: A total of 6,180 apparently healthy individuals participated in this study. Serum GR activity was measured using the AU5800 fully automated biochemical analyzer and its corresponding commercial kit. The Kolmogorov-Smirnov test was used to analyze the distribution of serum GR activity. Following the guidelines of C28-A3 and WS/T 402-2024, the reference interval for serum GR was determined using the bilateral percentile method, covering the range from the 2.5th to the 97.5th percentile.

Results: Serum GR activity in this study exhibited a non-normal distribution. Significant gender-based differences in GR activity were observed, while no significant variations were found across different age groups. Based on these findings, gender-specific reference intervals for serum GR were established: 26.6–51.8 U/l for males and 29.7–55.3 U/l for females.

Conclusions: This study is the first to establish gender-specific reference intervals for serum GR in apparently healthy adults. These intervals provide essential guidance for health screening and improve the diagnosis and management of related clinical conditions.

Key words: glutathione reductase, ultraviolet enzymatic method, reference interval, apparently healthy adults.

Introduction

Glutathione reductase (GR) is a homodimeric flavoprotein composed of 52 kDa monomers [1, 2]. In addition to its synthesis, the activity of GR provides a secondary source of reduced glutathione (GSH) in the cytosol

and certain organelles, such as the mitochondria [1, 2]. GR catalyzes the conversion of oxidized glutathione (GSSG) to GSH, maintaining high levels of GSH and low levels of GSSG within the organism, thereby preserving an appropriate reducing environment [1, 2]. Recent studies have highlighted the close relationship between GR levels in cells or blood and diseases such as Alzheimer's disease, Parkinson's disease, liver cancer, and colon cancer [3–6]. In particular, serum GR activity is significantly elevated in patients with infectious hepatitis, acute hepatitis, cirrhosis, and liver metastasis [7, 8]. Therefore, monitoring serum GR activity holds potential clinical value for the auxiliary diagnosis and prognosis of these conditions [3–8]. Thus, measuring serum GR in the laboratory can provide crucial support for the diagnosis and management of related diseases.

The reference interval is a critical component of laboratory reports, providing a fundamental basis for evaluating whether laboratory indicators fall within normal ranges. It plays a pivotal role in clinical decision-making, particularly in disease diagnosis and treatment [9, 10]. Currently, reference intervals for serum GR are predominantly derived from manufacturer guidelines. However, these intervals often lack broad applicability due to small sample sizes and insufficient stratification by gender and/or age. Consequently, there is a pressing need for laboratories to establish reference intervals that account for the specific lifestyle, gender, age, and methodological characteristics of the local population. Such tailored intervals would sig-

nificantly enhance the clinical utility of laboratory indicators [11, 12].

To date, few studies have focused on the establishment of GR reference intervals by laboratories, and the sample sizes in these studies have generally been small [13, 14]. In this study, we utilized the ultraviolet enzymatic method to measure serum GR activity in apparently healthy adults aged 20 to 79 years. The distribution of GR activity was analyzed, and reference intervals for serum GR were established in a single-center population in Jiangsu, Eastern China, in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) C28-A3 and WS/T 402-2024 [15, 16]. This study aims to provide a valuable foundation for the auxiliary diagnosis and treatment of clinically related diseases.

Material and methods

Study subjects

This study employed a completely randomized approach, initially selecting 7,200 individuals who underwent physical examinations at the Physical Examination Center of the Second People's Hospital of Lianyungang between January 2024 and June 2024. Based on predefined inclusion and exclusion criteria, 6,180 apparently healthy individuals were ultimately included, comprising 2,996 males and 3,184 females, aged 20 to 79 years. The screening process for research subjects is illustrated in Figure 1.

The inclusion criteria for this study were as follows: (1) aged 20–79 years with a body mass index (BMI) between 18.5 and 28 kg/m² (BMI ≥ 28 kg/m² was classified as obese); (2) normal blood pressure, defined as systolic blood pressure < 140 mm Hg and diastolic blood pressure < 90 mm Hg; (3) clinical biochemical indicators within normal reference ranges, including albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transferase (GGT), urea, creatinine (Cr), uric acid (UA), glucose (GLU), total cholesterol (TC), and triglycerides (TG); (4) negative immune markers for hepatitis A, B, C, and E; (5) complete blood count results within normal reference ranges; (6) no significant abnormalities detected through physical examination, chest X-ray, electrocardiogram, or abdominal ultrasound.

The exclusion criteria for this study were as follows: (1) digestive system diseases, including hepatitis, cirrhosis, fatty liver, cholelithiasis, cholecystitis, or inflammatory bowel disease; (2) acute or chronic infections, such as upper respiratory tract infections, pneumonia, or tuberculosis; (3) kidney diseases, including acute kidney injury and chronic kidney disease; (4) metabolic or nu-




Figure 1. Flowchart of reference individual recruitment

tritional disorders, such as diabetes, metabolic syndrome, hyperuricemia, or gout; (5) rheumatic diseases, including systemic lupus erythematosus and rheumatoid arthritis; (6) thyroid disorders, such as hyperthyroidism or hypothyroidism; (7) blood disorders, including leukemia and anemia; (8) recent history of blood donation, transfusion, significant blood loss, surgery, or medication use; (9) conditions such as malnutrition, vegetarianism, chronic alcohol consumption, heavy drinking within the past 2 weeks, or heavy smoking (≥ 20 cigarettes/day); (10) recent strenuous exercise or heavy physical labor; (11) pregnancy or breastfeeding in women.

Study design

Following the recommended methods outlined in the C28-A3 and WS/T 402-2024 guidelines [15, 16], subjects were initially categorized by gender. If a significant difference ($p < 0.05$) in serum GR activity was observed between genders, further subgrouping by age was performed. Both males and females were categorized into age groups: 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79. If significant differences ($p < 0.05$) in serum GR activity were found among age groups, the reference interval was established based on age. If no significant differences were observed, the reference interval was determined by combining all age groups.

Specimen collection

All subjects adhered to the standard procedures outlined in the Guidelines for Venous Blood Specimen Collection [17], using the same batch of sampling needles and blood collection tubes. The procedure was as follows: subjects maintained a normal diet and regular routines for 3 days prior to blood collection. On the morning of the fourth day, 5 ml of fasting venous blood was collected using yellow-capped tubes with separation gel. The samples were left to stand for 30 min to allow coagulation, then centrifuged (relative centrifugal force: 1000–1200 *g*, duration: 10 min). Serum was separated within 2 h and used for biochemical assays.

Analyzers and reagents

In this study, serum GR activity and other biochemical analytes were measured using the AU5800 automatic biochemical analyzer (Beckman Coulter, Brea, CA, USA) with the following commercial reagent kits: GR (lot: 20231027), ALB (lot: AUZ1574), ALT (lot: AUZ1963), AST (lot: AUZ2080), GGT (lot: AUZ2621), Urea (lot: AUZ2407), Cr (lot: 2541), UA (lot: AUZ2547), GLU (lot: AUZ2287), TC (lot: AUZ2280), and TG (lot: AUZ2697).

The detection methods used were: ultraviolet enzyme method for GR, bromocresol green method for ALB, rate method for ALT, AST, and GGT, urease-glutamate dehydrogenase method for urea, enzymatic method for Cr, uricase-peroxidase method for UA, hexokinase method for GLU, enzymatic method for TC, and phosphoglycerate oxidase-peroxidase method for TG. The GR test kit was manufactured by Jiangsu Maiyuan Biotechnology Co., Ltd., with a specified reference range of 33–73 U/l. The analyzer's performance was verified, and both internal quality control and external quality assessments were conducted in accordance with required standards.

Principle of serum GR activity determination

Serum GR activity was determined using the ultraviolet enzyme method as specified by the kit manufacturer. The principle is as follows: GR catalyzes the reduction of GSSG to GSH, while reduced coenzyme II (NADPH) is oxidized to NADP⁺. NADPH has a specific absorption peak at a wavelength of 340 nm, and its oxidation rate is proportional to the GR activity in serum. The GR activity is calculated by measuring the rate of decrease in NADPH absorbance at 340 nm.

Methods for validation of reference intervals

In this study, the direct method was used to establish the reference interval for serum GR. Accordingly, a small sample size was utilized for verification, following the guidelines outlined in WS/T 402-2024 [16]. The verification process is summarized as follows: (1) At least 20 qualified reference individuals were selected for each group, ensuring a balanced distribution of gender and age. The screening criteria were consistent with those used during the establishment of the reference interval. (2) Specimens were collected, processed, and tested in accordance with the laboratory's standard operating procedures. Prior to testing, the performance of the analytical system was verified to meet relevant requirements. (3) The Dixon method was applied to identify and exclude outliers. If the sample size became insufficient after outlier exclusion, additional samples were collected to maintain an adequate sample size. (4) Verification was considered successful if no more than 10% of the test results fell outside the established reference interval. If more than 10% of the data lay outside the interval, at least 20 additional qualified reference individuals were screened, and the verification process was repeated. (5) If verification was successful, the reference

Table I. General characteristics of reference individuals

Indicators	All (n = 6180)	Male (n = 2996)	Female (n = 3184)	Reference interval
Age [years]	51 (36, 67)	53 (36, 66)	50 (35, 67)	–
BMI [kg/m ²]	24.2 ±1.9	24.3 ±1.6	24.0 ±2.2	18.5–28.0
SBP [mm Hg]	123.3 ±7.9	125.4 ±6.3	121.2 ±8.6	90–139
DBP [mm Hg]	78.4 ±5.1	79.0 ±4.9	77.9 ±5.3	60–89
ALB [g/l]	46.7 ±3.2	48.0 ±3.2	45.6 ±2.7	40–55
ALT [U/l]	17.7 ±7.6	20.3 ±8.4	15.4 ±5.8	9.0–50.0 (male) 7.0–40.0 (female)
AST [U/l]	21.0 ±4.8	21.8 ±5.0	20.2 ±4.5	15.0–40.0 (male) 13.0–35.0 (female)
GGT [U/l]	20.6 ±8.5	24.6 ±9.2	16.8 ±5.5	10.0–60.0 (male) 7.0–45.0 (female)
Urea [mmol/l]	5.0 ±1.2	5.3 ±1.1	4.7 ±1.1	3.1–8.0 (male, aged 20–59 years) 3.6–9.5 (male, aged 60–79 years) 2.6–7.5 (female, aged 20–59 years) 3.1–8.8 (female, aged 60–79 years)
Crea [μmol/l]	65.2 ±12.6	74.9 ±9.4	56.1 ±7.3	57–97 (male, aged 20–59 years) 57–111 (male, aged 60–79 years) 41–73 (female, aged 20–59 years) 41–81 (female, aged 60–79 years)
UA [μmol/l]	297 ±61	336 ±53	261 ±43	208–428 (male) 155–357 (female)
GLU [mmol/l]	5.23 ±0.44	5.25 ±0.46	5.21 ±0.41	3.89–6.11
TC [mmol/l]	4.69 ±0.70	4.64 ±0.71	4.74 ±0.69	< 5.17
TG [mmol/l]	1.04 ±0.35	1.08 ±0.36	1.00 ±0.34	< 1.70


BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, ALB – albumin, ALT – alanine aminotransferase, AST – aspartate aminotransferase, GGT – γ -glutamyl transpeptidase, Crea – creatinine, UA – uric acid, GLU – glucose, TC – total cholesterol, TG – triglyceride.

interval could be adopted. If verification failed, the laboratory re-evaluated the reference individuals and ensured that the analytical quality met the required standards.

Statistical analyses

Inspection of outliers

Following our previous report [18], the Dixon method was used to analyze and remove outliers.

**Figure 2.** Distribution histogram of serum GR activity

Data analysis

Data analysis was performed using SPSS Statistics (IBM, Armonk, NY, USA), version 19. The Kolmogorov-Smirnov test was applied to assess the normality of the data. Data that conformed to a normal distribution were presented as mean ± standard deviation, while non-normally distributed data were reported as median (M) and interquartile range (IQR). For non-normally distributed data, comparisons between two groups were made using the Mann-Whitney *U* test, and comparisons among multiple groups were made using the Kruskal-Wallis test, followed by Dunn's post hoc test. The reference interval for serum GR was determined using the two-sided percentile method (2.5th percentile to 97.5th percentile). A *p*-value of less than 0.05 was considered statistically significant.

Results

General information and parameters of reference individuals

According to the study's inclusion and exclusion criteria, a total of 6,180 reference individuals were included. General information and indicators for all subjects, including gender, age, body mass

index, blood pressure, as well as levels of ALB, ALT, AST, GGT, urea, creatinine, uric acid, glucose, total cholesterol, and triglycerides, are presented in Table I.

Distribution of serum GR based on gender and age

The Kolmogorov-Smirnov test indicated that serum GR activity in healthy adults was not normally distributed (Figure 2).

Initially, we compared serum GR activity between males and females. The analysis revealed a statistically significant difference in serum GR activity between genders ($p < 0.05$; Table II).

Subsequently, the subjects were divided into six age groups to compare the distribution of serum GR activity and determine any age-related differences. The results showed no statistically significant differences in serum GR activity by age, for both males and females (all $p > 0.05$; Table III).

Establishment of reference intervals for serum GR

Based on the results, it was determined that gender factors should be considered when establishing the reference interval for serum GR, while age factors did not need to be considered. This study used a nonparametric method (two-sided percentile: 2.5th percentile to 97.5th percentile) to determine the reference interval for serum GR, in accordance with the C28-A3 and WS/T 402-2024 guidelines [15, 16]. Consequently, reference intervals for serum GR were established for apparently healthy adults in Eastern China using the ultraviolet enzyme method: 26.6–51.8 U/l for males and 29.7–55.3 U/l for females.

Additionally, to validate these reference intervals, we randomly selected samples from 20 males and 20 females, aged 20–79 years, all of whom were apparently healthy. For both males and females, over 90% of test results fell within the established reference intervals, demonstrating

Table II. Distribution of serum GR by gender

Gender	Number of individuals	Serum GR [U/l]			Mann-Whitney <i>U</i> test
		P ₂₅ (90% CI)	P ₅₀ (90% CI)	P ₇₅ (90% CI)	
Male	2996	36.7 (36.5–37.0)	40.3 (40.0–40.5)	44.1 (43.9–44.3)	$Z = -11.358$ $P = 0.001$
Female	3184	38.5 (38.4–38.7)	41.9 (41.7–42.1)	45.5 (45.3–45.7)	

CI – confidence interval.

Table III. Distribution of serum GR by age

Age group	Number of individuals	Serum GR [U/l]			Kruskal-Wallis <i>H</i> test
		P ₂₅ (90% CI)	P ₅₀ (90% CI)	P ₇₅ (90% CI)	
Male (aged 20–29)	416	36.2 (35.6–36.8)	39.8 (39.3–40.2)	44.6 (43.7–45.1)	$H = 9.986$ $P = 0.076$
Male (aged 30–39)	492	36.4 (35.7–37.0)	40.5 (39.8–40.1)	44.2 (43.6–44.8)	
Male (aged 40–49)	484	35.4 (34.9–36.6)	40.0 (39.5–40.7)	44.3 (43.7–46.5)	
Male (aged 50–59)	488	36.1 (35.4–36.8)	40.0 (39.3–40.5)	45.2 (44.2–46.0)	
Male (aged 60–69)	540	37.7 (36.5–38.2)	41.0 (40.6–41.2)	43.2 (43.0–43.6)	
Male (aged 70–79)	576	37.8 (37.5–38.5)	40.8 (40.3–41.2)	44.3 (44.1–44.5)	$H = 9.571$ $P = 0.088$
Female (aged 20–29)	572	38.5 (38.0–38.7)	41.6 (41.3–42.1)	45.3 (45.0–45.8)	
Female (aged 30–39)	484	38.3 (37.7–38.9)	41.5 (41.2–41.9)	45.2 (44.7–45.8)	
Female (aged 40–49)	496	38.8 (38.3–39.2)	42.2 (41.6–42.9)	46.3 (45.8–47.0)	
Female (aged 50–59)	536	36.9 (35.9–38.3)	42.2 (41.6–42.9)	45.8 (45.2–46.9)	
Female (aged 60–69)	512	39.7 (39.5–40.6)	42.7 (42.3–42.7)	45.3 (44.9–45.8)	
Female (aged 70–79)	584	38.5 (38.3–38.9)	40.8 (40.5–42.0)	46.4 (45.0–47.2)	

CI – confidence interval.

Table IV. Validation results for serum GR reference interval

Indicators	Reference interval [U/l]		Proportion of results in the reference interval (%)	Evaluation criteria (%)	Conclusion (Pass or fail)
	P _{2.5} (90% CI)	P _{97.5} (90% CI)			
GR (male)	26.6 (23.2–27.5)	51.8 (51.3–52.4)	95	≥ 90	Pass
GR (female)	29.7 (29.2–30.4)	55.3 (53.7–60.0)	100	≥ 90	Pass

CI – confidence interval.

that the intervals determined in this study are appropriate for clinical use (Table IV).

Discussion

Recently, the National Health Commission of China has established reference intervals for various laboratory indicators through multicenter studies, offering valuable insights into their clinical applications [19, 20]. It is important to recognize that the establishment of reference intervals is influenced by several factors, including population characteristics, geographical variations, and testing methodologies [21, 22]. Laboratories are required to verify the applicability of externally sourced reference intervals before adopting them [23, 24]. If verification is unsuccessful, it is recommended that laboratories establish reference intervals tailored to their specific regional populations [23, 24]. In this context, the present study is the first to investigate the distribution of serum GR activity in a single-center population of apparently healthy adults from Jiangsu province in Eastern China, and to establish its reference interval.

Based on the inclusion and exclusion criteria, a total of 6,180 reference individuals were included in this study. Our findings revealed that serum GR activity in healthy adults exhibited a non-normal distribution and significant gender differences, with females showing higher serum GR activity compared to males. After accounting for gender differences, the subjects were further stratified into age groups. The analysis indicated no statistically significant age-related differences in serum GR activity among healthy adults. In contrast, a study by Li *et al.* [13] reported slightly higher serum GR activity in men compared to women, though the difference was not statistically significant. Additionally, no significant age-related differences in serum GR activity were observed among men, whereas significant differences were noted among women. Conversely, Habib *et al.* [14], who investigated GR activity in erythrocytes from 130 healthy individuals, found no statistically significant differences in GR activity with respect to gender or age. The similarities and discrepancies between these studies and ours can be attributed to the following factors: (1) Population differences: The populations in the referenced studies were primarily from the Mediterranean region of Turkey and southern China, while the participants in this study were from eastern China. (2) Methodological variations: The referenced studies employed the GSSG substrate method or a modification of Beutler's method, while our study utilized the ultraviolet enzymatic method. (3) Specimen types: Habib *et al.* [14] measured GR activity in erythrocytes, whereas our study assessed GR activity in serum. (4) Sample size differences: The referenced

studies included 430 and 130 subjects, respectively, compared to the 6,180 individuals analyzed in this study [13, 14].

Based on the findings of this study and in accordance with the recommended methods outlined in the C28-A3 and WS/T 402-2024 guidelines, we established gender-specific reference intervals for serum GR activity in apparently healthy adults in eastern China: 26.6–51.8 U/l for males and 29.7–55.3 U/l for females. These intervals were validated using a smaller sample size, meeting the requirements for clinical application. Thus, the reference intervals established in this study provide valuable guidance for clinical practice. Comparatively, a study by Li *et al.* [13] preliminarily established reference intervals for serum GR activity in apparently healthy adults in Zhongshan, China, reporting ranges of 36–72 U/l for males, 38–65 U/l for females aged 18–50 years, and 45–67 U/l for females aged 51 years and older. Another study by Zheng *et al.* [25] cited the manufacturer's upper limit for serum GR activity as 73 U/l. Furthermore, the GR reference interval provided by Jiangsu Maiyuan Biotechnology Co., Ltd., the manufacturer of the GR kit used in this study, is 33–73 U/l. These intervals are generally higher than those established in our study. Both previous studies and our research underscore that serum GR reference intervals are closely influenced by factors such as regional characteristics, population demographics, sample size, and methodological variations. Therefore, laboratories must consider these factors when establishing reference intervals to maximize the clinical utility of laboratory indicators.

While this study provides significant insights, it has several limitations: (1) Restricted age range: The study included only healthy adults aged 20 to 79 years, excluding specific groups such as pregnant women, infants, and adolescents. Consequently, the established reference intervals may not apply to these populations. (2) Single-center design: Conducted at a single center with participants predominantly from the eastern coastal regions of China, the results may have limited applicability beyond this geographic area. Other laboratories should validate these reference intervals before application. (3) Narrow focus: The study concentrated exclusively on serum GR activity in apparently healthy individuals and did not investigate its role in diagnosing or managing clinically related diseases such as hepatitis, cirrhosis, or liver cancer. (4) Methodological limitations: This study employed an ultraviolet enzymatic method to assess serum GR activity. However, this approach does not measure GR activity directly but rather infers it indirectly based on the rate at which oxidized glutathione is reduced to its reduced form. To further enhance the clinical

utility of serum GR, future studies should include a broader range of populations, such as children, adolescents, and pregnant women, as well as participants from diverse geographic regions. Additionally, research should explore the role of serum GR in the diagnosis and management of related diseases to provide a more comprehensive understanding of its clinical relevance.

In conclusion, based on a single-center population in the Jiangsu region of eastern China, we established gender-specific reference intervals for serum GR in apparently healthy adults for the first time. These reference intervals will serve as a crucial guide for health screening and support the diagnosis and treatment of clinically relevant diseases.

Funding

This study was supported by the Key Project of the Research and Development Fund of Kangda College of Nanjing Medical University (KD2023KYJ048), the Key Project of the Natural Science Foundation of Bengbu Medical College (2022byzd175), the Lianyungang Cancer Prevention and Treatment Technology Development Plan Project (ZD202306, MS202309), and the Aging Health Research Project of the Lianyungang Health Committee (L202215, L202306).

Ethical approval

This study was approved by the Ethics Committee of the Second People's Hospital of Lianyungang (Approval No. 2024K014) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

Conflict of interest

The authors declare no conflict of interest.

References

1. Vašková J, Kočan L, Vaško L, et al. Glutathione-related enzymes and proteins: a review. *Molecules* 2023; 28: 1447.
2. Dalmazrak O, Terali K, Asuquo EB, et al. The relevance of glutathione reductase inhibition by fluoxetine to human health and disease: insights derived from a combined kinetic and docking study. *Protein J* 2019; 38: 515-24.
3. Yi L, Luo M, Wang M, et al. Fangchinoline alleviates cognitive impairments through enhancing autophagy and mitigating oxidative stress in Alzheimer's disease models. *Front Cell Dev Biol* 2023; 11: 1288506.
4. Tahavvori A, Gargari MK, Yazdani Y, et al. Involvement of antioxidant enzymes in Parkinson's disease. *Pathol Res Pract* 2023; 249: 154757.
5. Zheng Q, Xu X, Weng J, et al. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization. *Free Radic Biol Med* 2024; 221: 225-34.
6. Brzozowa-Zasada M, Piecuch A, Bajdak-Rusinek K, et al. Glutathione reductase expression and its prognostic significance in colon cancer. *Int J Mol Sci* 2024; 25: 1097.
7. Wróblewska J, Wróblewski M, Hołyńska-Iwan I, et al. The role of glutathione in selected viral diseases. *Antioxidants (Basel)* 2023; 12: 1325.
8. Wakui K, Kumata H, Tadaki H, et al. Clinical significance of serum glutathione reductase in various clinical conditions, especially in liver diseases. *Tohoku J Exp Med* 1976; 118: 17-23.
9. Liu Y, Zhang H, Wang J, et al. Reference values for exhaled nitric oxide in healthy children aged 6-18 years in China: a cross-sectional, multicenter clinical study. *Respir Res* 2024; 25: 340.
10. Janssen MJW, Dirks NF, Hillebrand JJ, et al. Age-specific reference intervals for TSH and FT4 to optimize diagnosis of thyroid disease. *Thyroid* 2024; 34: 1346-55.
11. Martínez-Espartosa D, Alegre E, Casero-Ramírez H, et al. Clinical utility of personalized reference intervals for CEA in the early detection of oncologic disease. *Clin Chem Lab Med* 2024. doi: 10.1515/cclm-2024-0546.
12. Liu Q, Xu A, Hang H, et al. Establishment of reference intervals for SII, NLR, PLR, and LMR in healthy adults in Jiangsu Region in Eastern China. *Clin Lab* 2023; 69. doi: 10.7754/Clin.Lab.2022.220837.
13. Li S, Lu S, Wang J, et al. Establishment of the reference intervals of serum glutathione reductase in apparently healthy adults. *Labor Med* 2019; 34: 908-12.
14. Habif S, Mutaf I, Turgan N, et al. Age and gender dependent alterations in the activities of glutathione related enzymes in healthy subjects. *Clin Biochem* 2001; 34: 667-71.
15. Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline (3rd ed). Wayne: PA, CLSI C28-A3, 2010.
16. The National Health Commission of the People's Republic of China. WS/T 402-2024 Defining, Establishing, and Verifying Reference Intervals of Quantitative Analytes in the Clinical Laboratory. Beijing: China Standard Press, 2024.
17. The National Health Commission of the People's Republic of China. WS/T 661-2020 Guidelines of venous blood specimen collection. Beijing: China Standard Press, 2020.
18. Liu Q, Fan J, Xu A, et al. Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults. *J Clin Lab Anal* 2019; 33: e22863.
19. The National Health Commission of the People's Republic of China. WS/T 404.10-2022 Reference Intervals for Common Clinical Biochemistry Tests Part 10: Serum Triiodothyronine, Thyroxine, Free Triiodothyronine, Free Thyroxine and Thyroid Stimulating Hormone. Beijing: China Standard Press, 2022.
20. The National Health Commission of the People's Republic of China. WS/T 780-2021 Reference Intervals of Clinical Biochemistry Tests Commonly Used for Children. Beijing: China Standard Press, 2021.
21. Li L, Li M, Zhu W, et al. Analytical performances of a novel fluorescent immunoassay of anti-Müllerian hormone and establishment of the reference intervals in Chinese children. *Pract Lab Med* 2024; 41: e00419.
22. France Štiglic A, Falnoga I, Briški AS, et al. Reference intervals of 24 trace elements in blood, plasma and erythrocytes for the Slovenian adult population. *Clin Chem Lab Med* 2023; 62: 946-57.

23. Zhang L, Chen Y, Hu R, et al. A single-center study of reference intervals for TAT, PIC, TM and t-PAIC in healthy older Chinese adults. *Thromb J* 2024; 22: 82.
24. Xu C, Chen X, Chen Y, et al. Establishment of age-specific reference intervals for serum 25-hydroxyvitamin D in a large pediatric population of Nanjing, China. *Heliyon* 2024; 10: e37409.
25. Zheng Q, Xu X, Weng J, et al. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization. *Free Radic Biol Med* 2024; 221: 225-34.